.Laura Van Metre Baum reveals a modest decline in #opioid prescriptions for patients with #cancer following surgery & a steep decline in opioid prescribing for pts with metastatic cancer w/o documented pain in review of pts at one healthcare system #ASCO24 Yale COPPER Center Yale School of Medicine Yale New Haven Hosp

Had so much fun presenting our Yale COPPER Center poster at ASCO Henry S. Park, MD, MPH Cary Gross Mayo Clinic Thanks to Yale, Mayo, and FDA colleagues Lots of excitement and interest in our findings!

Congratulations to MD Anderson Cancer Center and all the participating institutions for developing Level 1 evidence for proton therapy for oropharyngeal tumors Albert Koong, MD PhD PTCOG ASTRO PTCOG-NA National Association for Proton Therapy

Tragedy struck University of Maryland Radiation Oncology when PGY3 Dr. Muhammad Hamza was critically injured. After surgery, he's improving but prognosis is uncertain. We encourage our #radonc community to come together & support one of our own (GoFundMe link in photo below). 🫂 Life is precious ❤️

When something unfathomable happens to one of our own, we should come together and support 💜 Please consider donating for Muhammad and his 3-month old daughter. gofund.me/d6460eb4

Still on a high from #ASCO2024 and #ASCOLung- a surefire antidote to burnout! ⁦Gʀᴇɢᴏʀʏ Rɪᴇʟʏ⁩ ⁦Lauren Averett Byers, MD⁩ ⁦⁦Henry S. Park, MD, MPH⁩ ⁦Jyoti D Patel⁩ ⁦Jacob sands⁩

‼️ Impressive RCT showing reduction of ranibizumab treatment burden & cost using SBRT to treat neovascular age-related macular degeneration. Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR) - The Lancet thelancet.com/journals/lance… Nadeem Riaz

Registration is now open for the 2nd annual KoreanASTRO Dynamic Wedge Golf Tournament! koreanastro.org/golf-2024 Early registration $260 by 8/1/24! Regular $300 by 9/1/24

This table is some of my favorite female thoracic oncology experts 😍 and also I think we are the only SPORE table tonight with a full lung 🫁 tumor board!! Yale Thoracic Surgery Yale Cancer Center Christine Lovly, MD, PhD Henry S. Park, MD, MPH Dr. Kimryn Rathmell WomenInThoracicSurg Women in Oncology

Exciting work presented by our residents Dr. Kelly Becht and Patrick Oh at the National Cancer Institute annual #lungcancer SPORE workshop hosted by Yale Cancer Center Smilow Cancer Hospital! Henry S. Park, MD, MPH

BAD NEWS! -- Xevinapant +cis in HN Phase 3 negative at interim -- cis ineligible study closing down -- not great news for #hncsm #radonc NRG Oncology (h/t Yao Yu) C. Jillian Tsai, MD, PhD Sana Karam, MD, PhD Nancy Lee Henning Willers, MD emdgroup.com/en/news/xevina…

Congrats! IMRT to decrease lung and heart dose (not to mention esophagus) is critical for most patients receiving chemo-RT for LA-NSCLC.

Thoracic #RadOncs - check out our new paper in JACC CardioOnc! Simple heart features on planning CT were associated with risk of specific cardiac events after RT for NSCLC (n=478) Is it time we got Cardiology input on some of our patients? Thread (/14)...

We are thrilled to welcome the newest members of our team: Dr. Tomas Patrich, Dr. Mary-Kate Lawlor, and Dr. James Shen! First week of clinic as PGY-2 residents in the books ✅

Words cannot describe how profoundly sad I am to share the news of Dr. Shekinah Elmore's death this week. Shekinah was a SPECTACULAR human with profound wisdom, an incredible generosity of spirit, & a heart of kindness that lifted us all up. gofundme.com/f/honoring-dr-…

We're hiring for a position in Burlington, VT! Join our team committed to delivering high-quality, compassionate care in a collaborative and supportive environment Details & application link below. Feel free to reach out to me with questions #radonc 👇 uvmjobs.com/postings/74967

Third neoadjuvant FDA approval in NSCLC, now for perioperative durvalumab, based on Ph III AEGEAN trial: - 802pts, Stage IIA-IIIB NSCLC - plt dblet+durva q3 x4 ➡️ surgery ➡️durva q4 x 12 cycles - EFR HR 0.68 (p=0.0039), pCR rate 17% OncoAlert #LCSM fda.gov/drugs/resource…

I believe there is still equipoise regarding SBRT and immunotherapy. Let’s finish S1914 accrual (87% accrued) in the next few months since the design is quite different (2 cycles of neoadjuvant immunotherapy before SBRT, shorter duration of immunotherapy) and await PAC4 results!

Congrats to our fantastic multidisciplinary team on the world’s first SCINTIX-SBRT hybrid plan! Yale Radiation Oncology Residency Yale Cancer Center Yale School of Medicine

Using #SCINTIX, Smilow Cancer Hospital announced the successful delivery of the world’s first radiotherapy treatment plan combining different #radiotherapy modalities to treat a patient with #metastaticcancer. "For this patient, SCINTIX therapy treated the moving lung tumor, while #SBRT